Different Volatile Anaesthetics and the Depth of Long Term ICU Sedation
Launched by RUHR UNIVERSITY OF BOCHUM · Feb 28, 2019
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
The study was approved by the appropriate Institutional Review Board. Thirty ASA II-IV patients, undergoing elective or emergency surgery under general anaesthesia were included and randomized into three equal groups: ISO, SEVO or DES. We used MIRUS, a gas delivery system with a VA reflector, just like AnaConDa, that can be paired with common ICU ventilators. Additionally, MIRUS features the unique ability to maintain the end-tidal concentration (etVA) in target by automatically adjusting the delivery rate. Every 8 hours, the RASS was assessed by the nurse. The log of the EEG-Narcotrend Ind...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signing of the informed consent document (patient or relatives).
- • Patient age 18 years or older.
- • ASA I-III
- Exclusion Criteria:
- • ASA IV patients
- • Epidural or spinal analgesia
- • Allergy or known hypersensitivity to any of the study drugs
- • Patients with known or suspected genetic susceptibility to malignant hyperthermia
- • Previous participation in this trial
- • Participation in another clinical trial within 4 weeks prior to selection.
- • Pregnant women
About Ruhr University Of Bochum
Ruhr University Bochum is a prominent research institution located in Germany, renowned for its commitment to advancing medical science and improving healthcare outcomes through innovative clinical research. With a focus on interdisciplinary collaboration, the university actively engages in a range of clinical trials aimed at exploring novel therapeutic approaches and improving patient care. Its dedicated team of researchers and healthcare professionals work together to ensure the highest standards of scientific rigor and ethical conduct, contributing valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Thomas Weber, PhD
Principal Investigator
Ruhr University of Bochum, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials